Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $36.00 at The Goldman Sachs Group

Viridian Therapeutics (NASDAQ:VRDN) had its price target dropped by equities researchers at The Goldman Sachs Group from $41.00 to $36.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 81.70% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen cut shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. HC Wainwright reduced their price objective on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday. Evercore restated an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Wedbush dropped their target price on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Royal Bank Of Canada reduced their price target on Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.21.

Viridian Therapeutics Trading Up 6.9%

VRDN traded up $1.28 during trading on Tuesday, hitting $19.81. 1,317,251 shares of the stock were exchanged, compared to its average volume of 1,637,400. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $34.29. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65. The firm has a 50 day simple moving average of $29.42 and a 200 day simple moving average of $27.88. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -6.00 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $15.75 million. As a group, equities analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.

Insider Buying and Selling at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 2,272 shares of the stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.65% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its holdings in Viridian Therapeutics by 108.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after acquiring an additional 1,580,303 shares during the last quarter. Morgan Stanley raised its holdings in shares of Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after purchasing an additional 1,546,284 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $46,680,000. Vanguard Group Inc. lifted its position in shares of Viridian Therapeutics by 29.6% during the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Finally, Commodore Capital LP lifted its position in shares of Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 met its primary endpoint: elegrobart showed statistically significant proptosis responder rates (54% Q4W and 63% Q8W vs 18% placebo at week 24), providing a clear clinical efficacy signal for the subcutaneous candidate. Business Wire
• Positive Sentiment: Wedbush trimmed its price target (from $44 to $37) but kept an “outperform” rating — the new target implies roughly ~95% upside from current levels, signaling continued bullish conviction from a major shop. Benzinga
• Positive Sentiment: Needham cut its target (from $42 to $32) but maintained a “buy” rating, leaving a large implied upside (~67%), which likely supports near‑term buying interest after the sell‑off. Benzinga
• Neutral Sentiment: VRDN was mentioned on market roundups and podcasts (Bloomberg, Seeking Alpha) as a notable mover after the REVEAL‑1 release — these keep the name in traders’ screens but don’t change fundamentals directly. Bloomberg Podcast
• Negative Sentiment: Despite the positive readout, the stock plunged (>30%) on initial reaction as some investors parsed details (magnitude of effect by dosing arm, safety/labeling questions, or commercial assumptions). This swift sell‑off is a key reason for heightened volatility. Proactive Investors
• Negative Sentiment: Multiple news outlets highlighted the disconnect — “stock tumbles despite trial success” — reflecting investor concern or uncertainty about regulatory path, market uptake, or trial nuances. That narrative pressured the stock before today’s bounce. Investing.com
• Negative Sentiment: Several firms cut price targets: Wells Fargo lowered its target to $20 and set an “equal weight” rating (limited upside), and HC Wainwright trimmed its target to $22 while keeping a “buy” call — the cuts signal moderated near‑term expectations and contributed to selling pressure. Benzinga
• Negative Sentiment: Commentary and headlines from outlets (Bioworld, MSN) emphasized the market “sacking” or “plunging” reaction, reinforcing negative sentiment among short‑term traders. BioWorld

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.